A Gut Check on JAK Inhibitors: No Need to Drop the 5-ASA
A new multicenter cohort study provides crucial clinical guidance for managing ulcerative colitis. The research investigated whether continuing 5-aminosalicylic acid (5-ASA) alongside advanced Janus kinase inhibitor (JAKi) therapy—including tofacitinib, upadacitinib, and filgotinib—affects treatment outcomes. Analyzing data from 633 patients, the study found no significant difference in the time to achieve clinical remission between those taking concomitant 5-ASA and those who were not. At 48 weeks, the cumulative probability of remission was 81.3% with 5-ASA and 77.0% without, with an adjusted hazard ratio indicating no statistical benefit or detriment. This evidence suggests that for patients with ulcerative colitis transitioning to or maintained on JAK inhibitor therapy, the routine continuation of 5-ASA for its potential synergistic effect may be unnecessary, potentially simplifying complex treatment regimens.
Study Significance: This finding directly informs clinical decision-making in inflammatory bowel disease, allowing gastroenterologists to de-escalate therapy confidently without fearing a loss of efficacy. It challenges the common practice of maintaining background 5-ASA in all patients on advanced biologics or small molecules, potentially reducing polypharmacy, cost, and pill burden. For clinical trial design and treatment guidelines, it underscores the need to re-evaluate combination therapy strategies in ulcerative colitis management.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
